Generally tirzepatide can be used as a weight loss treatment for anyone with a BMI of 30 or higher, but there are certain people who are not suitable candidates for treatment, such as people who are trying to fall pregnant, are pregnant, or are breastfeeding
Depending on individual needs and doctors recommendations, the dosage may be increased to meet therapeutic goals
In SURPASS-2, which compared tirzepatide to semaglutide 1 mg in 1,879 patients with type 2 diabetes, tirzepatide 5 mg, 10 mg, and 15 mg reduced systolic blood pressure from baseline by 5.6, 7.4, and 8.0 mmHg respectively at 40 weeks, compared to 5.3 mmHg with semaglutide
Emerging evidence indicates GLP-1RA therapies not only influence overall appetite and satiety but also fundamentally alter food preference
Model-based metabolic pathway research : Investigating glucose and nutrient response pathways in experimental systems